Latest Car Inkt News

Page 2 of 2
Arovella Therapeutics reported solid progress in Q1 FY26, moving closer to initiating its first-in-human trial for ALA-101 while securing key patents and maintaining a strong cash position.
Ada Torres
Ada Torres
30 Oct 2025
Arovella Therapeutics has secured encouraging feedback from the US FDA on reagent testing for its CAR-iNKT cell therapy, setting the stage for an IND filing this quarter and clinical trials in early 2026.
Ada Torres
Ada Torres
28 Oct 2025
Arovella Therapeutics has demonstrated that its novel CLDN18.2 CAR-T cells effectively eliminate pancreatic cancer cells in vitro, matching the performance of a leading competitor’s product. The company is now advancing this CAR into its innovative iNKT cell platform to tackle solid tumours.
Ada Torres
Ada Torres
2 Oct 2025
Arovella Therapeutics reported a 14% reduction in net loss to $7.5 million for FY25, bolstered by a $15 million capital raise to fund its lead iNKT cell therapy program progressing toward a pivotal phase 1 clinical trial.
Ada Torres
Ada Torres
22 Aug 2025
Arovella Therapeutics reported a robust $20.9 million cash position as it prepares for its first-in-human trial of ALA-101 and expands its solid tumour pipeline through new licensing agreements and leadership appointments.
Ada Torres
Ada Torres
28 July 2025
Arovella Therapeutics has bolstered its financial position with a $20 million placement, fully funding the Phase 1 clinical trial of its lead CAR-iNKT therapy, ALA-101, targeting CD19-positive blood cancers. The company also established a Clinical Advisory Board and anticipates key regulatory and clinical milestones in 2025.
Ada Torres
Ada Torres
31 Jan 2025

Browse the archive

Full archive